Moderna Inc

NASDAQ:MRNA   3:03:46 PM EDT
101.23
+3.62 (+3.71%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)39.95B
Current PEN/A
Forward PE N/A
2yr Forward PE 23.27
See more stats
Estimates Current Quarter
Revenue$191.18 Million
Adjusted EPS-$0.62
See more estimates
10-Day MA$90.90
50-Day MA$74.75
200-Day MA$58.49
See more pivots

Moderna, Inc. Stock, NASDAQ:MRNA

200 TECHNOLOGY SQUARE, CAMBRIDGE, MA 02139
United States of America
Phone: 6177146500
Number of Employees: 760

Description

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.